Delray Medical Center Is 1st Hospital in Palm Beach County to Use Ensite X System

Delray Medical Center marks another milestone becoming the first hospital in Palm Beach County to use the new Ensite X EP System for cardiovascular EP procedures.  This technology uses HD images to collect data providing accurate and linear visualization for physicians to map out any area of the heart.  Electrophysiologist Dr. Yoel Vivas was the first physician in the county to use this new system at the hospital.

“I am truly honored to be able to perform the first procedure in Palm Beach County using the Ensite X System,” said Dr. Vivas. “Delray Medical Center is always looking at ways to invest in the latest life changing technology so we can provide the very best cardiac care to patients in our community.”

Some of the benefits to using the Ensite X technology include:

  • Redefined signal quality for mapping
  • Map 1,000,000 points without limitations
  • Address Bipolar Blindness capturing and enhancing better images
  • 10x faster mapping and data collection

“This is just another way we are providing top notch cardiovascular services to our patients who can get the highest quality care right here in Palm Beach County,” said Dr. Jean-Pierre Awaida, medical director of the catheterization-lab at Delray Medical Center. “The accuracy and imaging of this new device will give patients better outcomes and overall cardiovascular health.”

Delray Medical Center has an award winning cardiac program including:

  • Healthgrades Five-Star Recipient for Treatment of Heart Failure for 19 years in a row
  • Healthgrades Five-Star Recipient for Treatment of Heart Attack
  • Recipient of U.S. News & World Report High Performing Hospital for Heart Failure

For more information about our cardiac services, go to www.delraymedicalctr.com or call 561-498-4440.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”
Exit mobile version